Tilray (TLRY) Projected to Post Quarterly Earnings on Tuesday

Tilray (NASDAQ:TLRY - Get Free Report) is anticipated to announce its Q3 earnings results before the market opens on Tuesday, April 8th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $213.38 million for the quarter. Tilray has set its FY 2025 guidance at EPS.Individual that wish to register for the company's earnings conference call can do so using this link.

Tilray (NASDAQ:TLRY - Get Free Report) last released its quarterly earnings data on Tuesday, April 8th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.06). Tilray had a negative return on equity of 4.40% and a negative net margin of 30.95%. The company had revenue of $185.78 million for the quarter, compared to analyst estimates of $213.38 million. On average, analysts expect Tilray to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Tilray Stock Up 16.2 %

Shares of Tilray stock traded up $0.07 during trading hours on Wednesday, hitting $0.53. The company had a trading volume of 31,833,490 shares, compared to its average volume of 29,594,411. The company's 50-day moving average is $0.77 and its two-hundred day moving average is $1.20. Tilray has a twelve month low of $0.45 and a twelve month high of $2.52. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.54 and a quick ratio of 1.58. The company has a market cap of $497.05 million, a P/E ratio of -1.77 and a beta of 1.88.

Remove Ads

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on TLRY. Piper Sandler dropped their price objective on Tilray from $2.00 to $1.00 and set a "neutral" rating on the stock in a report on Wednesday. Canaccord Genuity Group upped their target price on Tilray from $2.00 to $3.00 and gave the company a "buy" rating in a research report on Monday, January 13th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $2.35.

Tilray Company Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.